Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression
{{output}}
Aurora kinases play critical roles in regulating several processes pivotal for mitosis. Radotinib, which is approved in South Korea as a second-line treatment for chronic myeloid leukemia, inhibits the tyrosine kinase BCR-ABL and platelet-derived growth factor... ...
